This is a competitive renewal application to further characterize the molecular and cellular facets of host immunity in high-risk corneal transplants, distinguished by their rapid and high-frequency rejection. The goal of these studies is to gain new insights into the mechanisms that distinguish high-risk vs. low-risk transplant immunity. Our overarching hypothesis is that high-risk corneal grafts are characterized by a microenvironment which at once abrogates the tolerogenic potential of corneal antigen-presenting cells while also rendering the host regulatory T cells dysfunctional. To test this concept, we have generated specific hypotheses: 1. The subverted immune homeostasis in high-risk grafts can be restored by (a) expansion of host regulatory T cells (Tregs) through enhanced CD25/IL-2R signaling (Aim 1), and (b) generation of tolerogenic antigen-presenting cells in the graft (Aim 2);and 2. The defective Treg function in high-risk grafts overrides the physiologic angiogenic privilege of the cornea, thus further amplifying the immune response against the graft (Aim 3). To test these specific hypotheses, we will pursue the following specific aims:
In Aim 1 A, we will investigate the differential frequencies and functional characteristics of 'natural'and 'induced'Tregs in low- and high-risk grafts, and determine the molecular bases for Treg dysfunction that we have established in high-risk transplants.
In Aim 1 B we will determine the efficacy of amplified CD25 signaling through low-dose interleukin-2 treatment in expanding and restoring Treg function in high-risk grafted hosts.
In Aim 2 we plan to continue our work enriching corneal donor buttons with tolerogenic antigen-presenting cells (tolAPC) through ex vivo conditioning, and to determine the effect of transplanting these tolAPC-enriched grafts on host sensitization, Treg frequency and function, and high-risk graft survival.
In Aim 3 we will evaluate the contribution of adaptive T cell-mediated immunity to corneal angiogenesis and lymphangiogenesis by comparing the function of effector T helper-1 cells vs. Tregs in abrogating vs. promoting corneal angiogenic privilege. Our study design relies on using the expertise of our laboratory along with use of well-characterized mouse models of corneal transplantation in conjunction with in vitro immunological and cell proliferation assays, and use of transgenic mice permitting us to monitor the differentiation and fate of Tregs so as to gain mechanistic insights into the molecular regulation of corneal alloimmunity. The overall health relevance of this research is that corneal grafting represents the number one form of transplantation performed in the United States. However, while most high-risk corneal transplant patients rapidly reject their grafts, there has been no significant change in the management or prognosis of high-risk transplantation in decades. The long-term objective is to use the data derived from these aims to develop new strategies to promote high-risk graft acceptance without the use of systemic immunosuppressive regimens which can be highly toxic.
High-risk corneal transplantation, performed in inflamed host graft beds, is characterized by swift and often irreversible immune rejection. While tens of thousands of these are performed annually on a global basis, there has been no significant change in the prognosis of high-risk grafts for decades. This grant proposes to study the mechanisms that are involved in induction of immunity to high-risk corneal transplants and develop novel strategies to promote tolerance and long-term survival of these grafts without use of toxic immunosuppressive medications.
|Chauhan, S K; Jurkunas, U; Funaki, T et al. (2015) Quantification of allospecific and nonspecific corneal endothelial cell damage after corneal transplantation. Eye (Lond) 29:136-44|
|Crnej, Alja; Omoto, Masahiro; Dohlman, Thomas H et al. (2014) A novel murine model for keratoprosthesis. Invest Ophthalmol Vis Sci 55:3681-5|
|Emami-Naeini, Parisa; Dohlman, Thomas H; Omoto, Masahiro et al. (2014) Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival. Graefes Arch Clin Exp Ophthalmol 252:1755-62|
|Hua, Jing; Jin, Yiping; Chen, Yihe et al. (2014) The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation. Invest Ophthalmol Vis Sci 55:5944-51|
|Chauhan, Sunil K; Saban, Daniel R; Dohlman, Thomas H et al. (2014) CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue. J Immunol 192:817-23|
|Ferrari, Giulio; Hajrasouliha, Amir R; Sadrai, Zahra et al. (2013) Nerves and neovessels inhibit each other in the cornea. Invest Ophthalmol Vis Sci 54:813-20|
|Hajrasouliha, Amir R; Funaki, Toshinari; Sadrai, Zahra et al. (2012) Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci 53:1244-50|
|Stevenson, William; Cheng, Sheng-Fu; Dastjerdi, Mohammad H et al. (2012) Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 10:67-83|
|Zhang, Duan-Sun; Piazza, Valeria; Perrin, Benjamin J et al. (2012) Multi-isotope imaging mass spectrometry reveals slow protein turnover in hair-cell stereocilia. Nature 481:520-4|
|Hajrasouliha, Amir R; Sadrai, Zahra; Chauhan, Sunil K et al. (2012) b-FGF induces corneal blood and lymphatic vessel growth in a spatially distinct pattern. Cornea 31:804-9|
Showing the most recent 10 out of 57 publications